Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Research Antwerp
Shanghai Henlius Biotech
Hoffmann-La Roche
Tianjin Medical University Cancer Institute and Hospital
SWOG Cancer Research Network
NRG Oncology
Shanghai Jiao Tong University School of Medicine
SWOG Cancer Research Network
Ukrainian Society of Clinical Oncology